摘要:
The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM), e.g., compositions comprising virus-like particles (VLPs) comprising Moloney Murine leukemia virus (MMLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with GM-CSF, which, at dose of at least 10 pg gB/pp65Gag, reverse dysregulation of anti-HCMV immunity in GBM patients.
摘要:
Described are compositions and methods for removing one or more host cell proteins from a mixture. The composition comprises one or more peptides wherein each peptide in the composition has a greater binding affinity for the one or more host cell proteins than for one or more target biomolecules.
摘要:
Provided herein is a modified, non-reovirus comprising a reovirus sigma 1 protein, wherein the reovirus sigma 1 protein replaces the native attachment protein of the non-reovirus. Methods of making a modified, non-reovirus comprising a reovirus sigma 1 protein and methods of using said modified non-reovirus are also provided.
摘要:
The invention relates to a method for producing a modified viral strain of a virus which is a member of the Reoviridae family and, in particular, relates to vaccinal viral strains of the Orbivirus genus.
摘要:
The present invention provides for a mutant reovirus and a genetically-engineered ISVP. Specifically, the present invention provides a mutant reovirus that lacks or exhibits a reduced expression of the sigma3 polypeptide or that lacks a functional sigma3 polypeptide. The mutant reovirus described therein can be used to generate and stably propagate ISVP. Compositions including the mutant reovirus and methods of using such mutant reovirus are also provided.
摘要:
Peptides chélatant l'uranium ainsi que leurs applications pour la décontamination des sols et des eaux, ainsi que pour la détection et le traitement des personnes contaminées par l'uranium. Lesdits peptides possèdent une structure du type hélice-boucle-hélice comprenant la séquence d'une boucle de la calmoduline incluant au moins une mutation en résidus neutres sélectionnés dans le groupe constitué par S, T, C, H,Y, N et Q, d'un, deux ou trois résidus d'au moins l'un des quatre sites de fixation du calcium de la calmoduline : site I : résidus sélectionnés parmi les résidus D20, D22 et D24, site II : résidus sélectionnés parmi les résidus D56, D58 et N60, site III : résidus sélectionnés parmi les résidus D93, D95 et N97, site IV : résidus sélectionnés parmi les résidus D129, D131 et D133, lesdites positions étant indiquées en référence à la séquence de la calmoduline humaine.
摘要:
The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence.
摘要:
This invention relates to a method of potentiating an immune response by administering a viral enterotoxin or derivative as an adjuvant. More particularly it relates to administering a viral enterotoxin or derivative as an adjuvant and an antigen to a mucosal surface of a mammal. Figure 1 shows the antibody responses evaluated by enzyme-linked immunosorbent assays of serum immunoglobulin immune response to keyhole limpet hemocyanin administered intranasally in the presence or absence of rotavirus enterotoxin or labile toxin.
摘要:
Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide sequence encoding the immune modulatory molecule, which is preferably a cytokine. Introduction of the cytokine increase, decrease, or otherwise enhances aspects of viral biology and/or host immune responses to RSV to facilitate vaccine use of the virus. Cytokines for use within the invention include but are not limited to interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), or interleukin 18 (IL-18), tumor necrosis factor (TNF) alpha, interferon gamma (IFN), and granulocyte-macrophage colony stimulating factor (GM-CSF). The polynucleotide or immune modulatory molecule is preferably added or substituted into the recombinant viral genome or antigenome, typically at an intergenic or other non-coding site, as a separate gene but may be otherwise expressed, for example as a fusion protein.
摘要:
This invention relates to a method of potentiating an immune response by administering a viral enterotoxin or derivative as an adjuvant. More particularly it relates to administering a viral enterotoxin or derivative as an adjuvant and an antigen to a mucosal surface of a mammal. Figure 1 shows the antibody responses evaluated by enzyme-linked immunosorbent assays of serum immunoglobulin immune response to keyhole limpet hemocyanin administered intranasally in the presence or absence of rotavirus enterotoxin or labile toxin.